Absci is using an AI-powered approach to translate ideas into human monoclonal antibody drugs. Their approach, called Integrated Drug Creation, is a platform that connects technology with innovative ideas from Absci’s proprietary data. Absci then applies synthetic biology to create and produce next-generation biologics, unifying drug discovery and cell line development into a single process. Generating non-obvious predictions for optimal drug candidates for any protein target depends on Absci’s Denovium Engine AI models that makes a solution space of sequences beyond what exists in nature. The entire process generates data that can be used to improve the platform - Absci’s ultimate aim is to make drug design fully in silico. 

Absci

Associate Director, Bioassays

Operations Excellence Partner (OpEx)

Absci

Company info:

About company:

Jobs: